Daily Intelligence Brief
Suboxone Filings Swell as Social Media Addiction and Depo-Provera Dockets Expand
Pharmaceutical and consumer product liability claims dominated the federal mass-tort landscape, driving a surge in daily filing activity led by a massive influx of litigation over prescription treatments. A wave of 136 new lawsuits alleging that the opioid dependence treatment causes severe dental decay propelled the Suboxone (Buprenorphine/Naloxone) Film Products Liability Litigation (MDL 3092) to the forefront of the daily volume, with firms like Andrews & Higgins and Flint Cooper active on the docket. Meanwhile, digital safety and women's health claims continued to expand, as the Social Media Adolescent Addiction Personal Injury Products Liability Litigation (MDL 3047) added 36 cases, led by Wright & Schulte LLC and Keller Postman LLC, while the Depo-Provera (Depot Medroxyprogesterone Acetate) Products Liability Litigation (MDL 3140) generated 20 new filings spearheaded by McSweeney Langevin LLC and Frazer PLC. Cosmetic and chemical safety concerns also maintained steady volume, with 18 complaints filed in the Hair Relaxer Marketing, Sales Practices, and Products Liability Litigation (MDL 3060) by firms including Ashcraft Gerel LLP and the Cochran Firm, and 14 new actions added to the mature Johnson & Johnson Talcum Powder Products Marketing, Sales Practices and Products Liability Litigation (MDL 2738) docket, driven primarily by The Miller Firm LLC and Davis & Bethune. See the full filing feed and firm-level breakdowns here.
Clergy Abuse Survivors Support $326 Million Settlement with Buffalo Diocese
On June 16, 2026, a representative panel for clergy sex abuse survivors advocated for a $326 million settlement in the In re Diocese of Buffalo Chapter 11 bankruptcy case, marking a critical milestone to compensate nearly 900 victims of abuse. The proposed agreement, which concludes more than six years of contentious legal proceedings, will be funded by a $150 million contribution from the diocese, its parishes, and other Catholic entities, alongside $176 million from various insurance carriers. Under the terms of the settlement, funds are projected to be distributed to survivors by late 2026 or early 2027, pending a scheduled disclosure statement hearing in August and a subsequent vote by the claimants in the fall. Survivors on the diocese's unsecured creditors' committee, who spoke publicly for the first time on June 15, emphasized that while the financial package represents a hard-fought resolution, they continue to demand formal apologies and systemic institutional reform. Legal analysts expect the settlement to serve as a critical benchmark for other bankrupt dioceses nationwide grappling with legacy abuse claims.
Federal Judge Remands Kanaga Roundup Lawsuit to Ohio State Court
On June 12, 2026, the U.S. District Court for the Northern District of Ohio issued a ruling to remand the products liability case Kanaga v. Monsanto Company (No. 1:25-cv-2786) back to the Cuyahoga County Court of Common Pleas, rejecting the manufacturer's attempt to keep the litigation in federal court. The wrongful death lawsuit, which alleges that exposure to Monsanto's glyphosate-based weedkiller Roundup caused decedent Glenn Kanaga's Hodgkin's lymphoma and subsequent death, falls outside the federal Roundup Products Liability Litigation (MDL 2741), which covers non-Hodgkin's lymphoma claims. The Kanagas had briefly been transferred into MDL 2741 after a 2023 federal filing but were removed from its settlement program over the Hodgkin's diagnosis; following Glenn Kanaga's death in late 2024, his family filed this new state-court wrongful death suit in December 2025. Monsanto had removed the case to federal court, claiming that local Ohio defendants Dunn Hardware, LLC and Scotts Miracle-Gro Company were fraudulently joined to defeat diversity jurisdiction. However, the federal judge determined that the plaintiffs asserted a colorable wrongful death/supplier liability claim against the local hardware store (Dunn Hardware) under state law, thereby destroying complete diversity and forcing the remand. This procedural victory allows the plaintiffs to pursue their claims in state court, highlighting the ongoing jurisdictional battles as defendants seek federal forums while plaintiffs utilize local retail entities to anchor their cases in state courts.
Generated by LexGenius Feed. Signals sourced from PACER federal court dockets, FDA/OpenFDA adverse event database, Federal Register, PubMed, and Google News.